Loading...

PASG PASSAGE BIO INC Capital Structure Changes 8-K Filing

PSSG

PSG

PASSAGE BIO INC

(PASG)

2026 8-K

Workforce Restructuring

Clinical Trial Update

Lease Termination

Financial Results Update

Cash Position Update

Financial Update

Board Resignation

Voluntary Delisting

Product Expansion

Management Changes

Financial Statements

Financial Results

Nasdaq Compliance

Restructuring Plan

Financial Results

Scientific Presentation

Clinical Trial Update

Director Appointment

Sublease Agreement

Financial Results and Corpo...

Sublicense Agreements

FDA Feedback on PBFT02 for ...

Annual Meeting of Stockholders

Earnings Reports

Financial Results and CFO A...

Compliance with Nasdaq List...

Regulation FD Disclosure

Settlement Agreement

PBFT02 Program Updates

Earnings Release

Delisting Notice

Earnings Report & Conferenc...

Departure and Appointment o...

Management Changes

Annual Meeting of Stockholders

Financial Results and Corpo...

Agreement Amendments with C...

FDIC Receiver of Silicon Va...

Earnings Reports

Presentation and Press Release

Financial Update

External Links:

On January 12, 2026, Passage Bio, Inc. reported that its preliminary cash, cash equivalents, and marketable securities total approximately $46 million as of December 31, 2025, expected to fund operations into Q1 2027.

AI Assistant

PASSAGE BIO INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.